Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Ianalumab by Novartis for Hidradenitis Suppurativa: Likelihood of Approval
Ianalumab is under clinical development by Novartis and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II...
Ianalumab by Novartis for Rheumatoid Arthritis: Likelihood of Approval
Ianalumab is under clinical development by Novartis and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II...
Ianalumab by Novartis for Systemic Sclerosis (Scleroderma): Likelihood of Approval
Ianalumab is under clinical development by Novartis and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Novartis's Ianalumab?
Ianalumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Sicca Syndrome (Sjogren). According to...
Risk adjusted net present value: What is the current valuation of Novartis's Ianalumab?
Ianalumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Acquired (Autoimmune) Hemolytic Anemia;Idiopathic Thrombocytopenic...